Q-omics provides the consensus-scored EXD2 profile across patient tissues and cancer cell-line models. EXD2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EXD2 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, EXD2 RNA expression shows 20,672 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where EXD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EXD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EXD2 survival associations across molecular data types. EXD2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EXD2 RNA expression–survival associations across cancer types. High EXD2 expression shows unfavorable associations in ACC, LIHC and CESC, but favorable associations in KIRC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EXD2 RNA expression.
This table summarizes EXD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EXD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EXD2 shows lower tumor expression in THCA and KIRC and higher tumor expression in CHOL, LIHC, ESCA and PRAD. The THCA box plot shows higher EXD2 RNA expression in normal versus tumor tissue (log2 FC = −0.821, t-test p < 0.001).
This table shows molecular features associated with EXD2 in patient tissues and cancer cell lines. In patient samples, EXD2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EXD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
